Table 4.
Association between diabetes and primary anti-tuberculosis drug resistance
| Type | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| OR (95%CI) | P-value | aOR (95%CI) | P-value | |
| Any DR-TB | 1.20 (0.94–1.51) | 0.14 | 1.30 (1.02–1.65) | 0.04* |
| INH-related resistance | 1.18 (0.87–1.60) | 0.28 | 1.24 (0.92–1.69) | 0.16 |
| RFP-related resistance | 1.29 (0.86–1.96) | 0.22 | 1.45 (0.94–2.23) | 0.09 |
| SM-related resistance | 1.28 (0.98–1.67) | 0.07 | 1.43 (1.08–1.88) | 0.01* |
| INH+SM resistance | 1.50 (0.94–2.37) | 0.09 | 1.53 (0.95–2.44) | 0.08 |
| MR-TB | 1.06 (0.78–1.44) | 0.70 | 1.17 (0.86–1.60) | 0.32 |
| PDR-TB | 1.57 (1.04–2.36) | 0.03* | 1.59 (1.04–2.44) | 0.03* |
| MDR-TB | 1.19 (0.72–1.97) | 0.50 | 1.36 (0.81–2.28) | 0.25 |
| Pan susceptible | Reference | Reference | Reference | Reference |
Note: *P<0.05.
Abbreviations: DR-TB, drug-resistant tuberculosis; MR-TB, monoresistant tuberculosis; MDR-TB, multiresistant tuberculosis; PDR-TB, polydrug resistant tuberculosis; INH, isoniazid; RFP, rifampin; SM, streptomycin.